TY - JOUR
T1 - Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm
AU - Ardeshirpour, Yasaman
AU - Chernomordik, Victor
AU - Capala, Jacek
AU - Hassan, Moinuddin
AU - Zielinsky, Rafal
AU - Griffiths, Gary
AU - Achilefu, Samuel
AU - Smith, Paul
AU - Gandjbakhche, Amir
PY - 2011/12
Y1 - 2011/12
N2 - The major goal in developing drugs targeting specific tumor receptors, such as Monoclonal AntiBodies (MAB), is to make a drug compound that targets selectively the cancer-causing biomarkers, inhibits their functionality, and/or delivers the toxin specifically to the malignant cells. Recent advances in MABs show that their efficacy depends strongly on characterization of tumor biomarkers. Therefore, one of the main tasks in cancer diagnostics and treatment is to develop non-invasive in-vivo imaging techniques for detection of cancer biomarkers and monitoring their down regulation during the treatment. Such methods can potentially result in a new imaging and treatment paradigm for cancer therapy. In this article we have reviewed fluorescence imaging approaches, including those developed in our group, to detect and monitor Human Epidermal Growth Factor 2 (HER2) receptors before and during therapy. Transition of these techniques from the bench to bedside is the ultimate goal of our project. Similar approaches can be used potentially for characterization of other cancer related cell biomarkers.
AB - The major goal in developing drugs targeting specific tumor receptors, such as Monoclonal AntiBodies (MAB), is to make a drug compound that targets selectively the cancer-causing biomarkers, inhibits their functionality, and/or delivers the toxin specifically to the malignant cells. Recent advances in MABs show that their efficacy depends strongly on characterization of tumor biomarkers. Therefore, one of the main tasks in cancer diagnostics and treatment is to develop non-invasive in-vivo imaging techniques for detection of cancer biomarkers and monitoring their down regulation during the treatment. Such methods can potentially result in a new imaging and treatment paradigm for cancer therapy. In this article we have reviewed fluorescence imaging approaches, including those developed in our group, to detect and monitor Human Epidermal Growth Factor 2 (HER2) receptors before and during therapy. Transition of these techniques from the bench to bedside is the ultimate goal of our project. Similar approaches can be used potentially for characterization of other cancer related cell biomarkers.
KW - Affibody
KW - Cancer diagnostics
KW - Cancer treatment
KW - Fluorescence imaging
KW - Human epidermal growth factor receptor
KW - Near infrared optical imaging
KW - Targeted fluorescent probe
UR - http://www.scopus.com/inward/record.url?scp=82755179477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82755179477&partnerID=8YFLogxK
U2 - 10.1177/153303461101000605
DO - 10.1177/153303461101000605
M3 - Review article
C2 - 22066595
AN - SCOPUS:82755179477
SN - 1533-0346
VL - 10
SP - 549
EP - 560
JO - Technology in Cancer Research and Treatment
JF - Technology in Cancer Research and Treatment
IS - 6
ER -